XNASAURA
Market cap386mUSD
Jan 15, Last price
7.73USD
1D
2.25%
1Q
-24.88%
IPO
-49.48%
Name
Aura Biosciences Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-76m
L+33.51%
CFO
-64m
L+16.93%
Earnings
Jun 20, 2025
Profile
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 86,286 | 61,472 | |||
Unusual Expense (Income) | |||||
NOPBT | (86,286) | (61,472) | |||
NOPBT Margin | |||||
Operating Taxes | 137 | (1,532) | |||
Tax Rate | |||||
NOPAT | (86,423) | (59,940) | |||
Net income | (76,408) 33.51% | (57,231) 66.27% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 3,170 | 8,549 | |||
BB yield | -0.90% | -2.72% | |||
| Debt | |||||
Debt current | 5,374 | 2,963 | |||
Long-term debt | 36,427 | 38,753 | |||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | (184,349) | (147,863) | |||
| Cash flow | |||||
Cash from operating activities | (63,847) | (54,601) | |||
CAPEX | (709) | (1,094) | |||
Cash from investing activities | (113,963) | (67,869) | |||
Cash from financing activities | 97,290 | 95,629 | |||
FCF | (82,008) | (80,158) | |||
| Balance | |||||
Cash | 226,150 | 188,811 | |||
Long term investments | 768 | ||||
Excess cash | 226,150 | 189,579 | |||
Stockholders' equity | (286,769) | (210,972) | |||
Invested Capital | 534,861 | 427,413 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 39,620 | 29,937 | |||
Price | 8.86 -15.62% | 10.50 -38.16% | |||
Market cap | 351,034 11.67% | 314,341 -36.63% | |||
EV | 166,685 | 166,478 | |||
EBITDA | (84,991) | (60,295) | |||
EV/EBITDA | |||||
Interest | 850 | ||||
Interest/NOPBT | |||||